• Je něco špatně v tomto záznamu ?

Cyclomodulins and Hemolysis in E. coli as Potential Low-Cost Non-Invasive Biomarkers for Colorectal Cancer Screening

K. Mezerová, L. Starý, P. Zbořil, I. Klementa, M. Stašek, P. Špička, P. Skalický, V. Raclavský

. 2021 ; 11 (11) : . [pub] 20211031

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001412

Grantová podpora
IGA_LF_2021_022 the Faculty of Medicine & Dentistry, Palacký University Olomouc
DRO 61989592 the Ministry of Education, Youth and Sports, Czech Republic
DROFNOl 00098892, NV19-03-00069 the Ministry of Health, Czech Republic

The frequent occurrence of E. coli positive for cyclomodulins such as colibactin (CLB), the cytotoxic necrotizing factor (CNF), and the cytolethal distending factor (CDT) in colorectal cancer (CRC) patients published so far provides the opportunity to use them as CRC screening markers. We examined the practicability and performance of a low-cost detection approach that relied on culture followed by simplified DNA extraction and PCR in E. coli isolates recovered from 130 CRC patients and 111 controls. Our results showed a statistically significant association between CRC and the presence of colibactin genes clbB and clbN, the cnf gene, and newly, the hemolytic phenotype of E. coli isolates. We also observed a significant increase in the mean number of morphologically distinct E. coli isolates per patient in the CRC cohort compared to controls, indicating that the cyclomodulin-producing E. coli strains may represent potentially preventable harmful newcomers in CRC patients. A colibactin gene assay showed the highest detection rate (45.4%), and males would benefit from the screening more than females. However, because of the high number of false positives, practical use of this marker must be explored. In our opinion, it may serve as an auxiliary marker to increase the specificity and/or sensitivity of the well-established fecal immunochemical test (FIT) in CRC screening.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001412
003      
CZ-PrNML
005      
20220112153601.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/life11111165 $2 doi
035    __
$a (PubMed)34833041
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mezerová, Kristýna $u Department of Microbiology, Faculty of Medicine & Dentistry, Palacký University Olomouc, Hněvotínská 3, 775 15 Olomouc, Czech Republic
245    10
$a Cyclomodulins and Hemolysis in E. coli as Potential Low-Cost Non-Invasive Biomarkers for Colorectal Cancer Screening / $c K. Mezerová, L. Starý, P. Zbořil, I. Klementa, M. Stašek, P. Špička, P. Skalický, V. Raclavský
520    9_
$a The frequent occurrence of E. coli positive for cyclomodulins such as colibactin (CLB), the cytotoxic necrotizing factor (CNF), and the cytolethal distending factor (CDT) in colorectal cancer (CRC) patients published so far provides the opportunity to use them as CRC screening markers. We examined the practicability and performance of a low-cost detection approach that relied on culture followed by simplified DNA extraction and PCR in E. coli isolates recovered from 130 CRC patients and 111 controls. Our results showed a statistically significant association between CRC and the presence of colibactin genes clbB and clbN, the cnf gene, and newly, the hemolytic phenotype of E. coli isolates. We also observed a significant increase in the mean number of morphologically distinct E. coli isolates per patient in the CRC cohort compared to controls, indicating that the cyclomodulin-producing E. coli strains may represent potentially preventable harmful newcomers in CRC patients. A colibactin gene assay showed the highest detection rate (45.4%), and males would benefit from the screening more than females. However, because of the high number of false positives, practical use of this marker must be explored. In our opinion, it may serve as an auxiliary marker to increase the specificity and/or sensitivity of the well-established fecal immunochemical test (FIT) in CRC screening.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Starý, Lubomír $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
700    1_
$a Zbořil, Pavel $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
700    1_
$a Klementa, Ivo $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
700    1_
$a Stašek, Martin $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
700    1_
$a Špička, Petr $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
700    1_
$a Skalický, Pavel $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
700    1_
$a Raclavský, Vladislav $u Department of Microbiology, Faculty of Medicine & Dentistry, Palacký University Olomouc, Hněvotínská 3, 775 15 Olomouc, Czech Republic
773    0_
$w MED00186366 $t Life (Basel, Switzerland) $x 2075-1729 $g Roč. 11, č. 11 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34833041 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153557 $b ABA008
999    __
$a ind $b bmc $g 1745467 $s 1152559
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 11 $e 20211031 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
GRA    __
$a IGA_LF_2021_022 $p the Faculty of Medicine & Dentistry, Palacký University Olomouc
GRA    __
$a DRO 61989592 $p the Ministry of Education, Youth and Sports, Czech Republic
GRA    __
$a DROFNOl 00098892, NV19-03-00069 $p the Ministry of Health, Czech Republic
LZP    __
$a Pubmed-20220107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...